Loading
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer, run by Celltrion, active and no longer recruiting.
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer is a phase 3 interventional study registered as NCT06939595 by Celltrion, with 225 participants enrolled, started 2025-01-30 and due to reach its primary completion in 2027-02. Interventions recorded: CT-P51 and EU-approved Keytruda.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/